For good and ill, immune response to cancer cuts both ways

April 7, 2014, University of California - San Diego

The difference between an immune response that kills cancer cells and one that conversely stimulates tumor growth can be as narrow as a "double-edged sword," report researchers at the University of California, San Diego School of Medicine in the April 7, 2014 online issue of the Proceedings of the National Academy of Sciences.

"We have found that the intensity difference between an that stimulates cancer and one that kills it may not be very much," said principal investigator Ajit Varki, MD, Distinguished Professor of Medicine and Cellular and Molecular Medicine. "This may come as a surprise to researchers exploring two areas typically considered distinct: the role of the immune system in preventing and killing cancers and the role of chronic inflammation in stimulating cancers. As always, it turns out that the is a double-edged sword."

The concept of naturally occurring "immunosurveillance" against malignancies is not new, and there is compelling evidence for it. But understanding this process is confounded by the fact that some types of promote . Varki and colleagues looked specifically at a non-human sialic acid sugar molecule called Neu5Gc. Previous research has found that Neu5Gc accumulates in human tumors from dietary sources, despite an on-going antibody response against it.

The scientists deployed antibodies against Neu5Gc in a human-like mouse model to determine whether and to what degree the antibodies altered . They found that low antibody doses stimulated growth, but high doses inhibited it. The effect occurred over a "linear and remarkably narrow range," said Varki, generating an immune response curve or "inverse hormesis." Moreover, this curve could be shifted to the left or right simply by modifying the quality of the immune response.

Similar findings were made in experiments with two other mouse tumor models, and with a human tumor xenograft model using a monoclonal antibody currently in clinical use. The scientists concluded that the difference in intensity between an immune response stimulating tumors and one that kills them may be much less than previously imagined.

Varki said the results may have implications for all aspects of cancer science, from studying its causes to prevention and treatment. This is because the immune response can have multiple roles in the genesis of cancers, in altering the progress of established tumors and in anti-cancer therapies that use antibodies as drugs.

Explore further: A cancer marker and treatment in one? Researchers finds promise in non-human sialic acid antibodies

More information: The findings will be presented at the annual meeting of the American Association for Cancer Research in San Diego, April 5 to 9.

PNAS paper: Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies, www.pnas.org/cgi/doi/10.1073/pnas.1209067111

Related Stories

A cancer marker and treatment in one? Researchers finds promise in non-human sialic acid antibodies

April 19, 2011
Researchers at the University of California, San Diego School of Medicine say antibodies to a non-human sugar molecule commonly found in people may be useful as a future biomarker for predicting cancer risk, for diagnosing ...

Disruption of VISTA plays an important role in regulating immune response

April 7, 2014
Researchers at the Geisel School of Medicine at Dartmouth have found that the body's immune system response was enhanced when they disrupted VISTA, a protein that prevents the immune system from overreacting. Understanding ...

The immune system's redesigned role in fighting cancerous tumors

March 12, 2014
Researchers in the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute eradicated solid tumors in laboratory mice using a novel combination of two targeted agents. These two synergistic therapies stimulate an immune ...

Infecting just one tumor with a virus could boost the systemic effectiveness of cancer immunotherapy

March 5, 2014
A Ludwig Cancer Research study suggests that the clinical efficacy of checkpoint blockade, a powerful new strategy to harness the immune response to treat cancers, might be dramatically improved if combined with oncolytic ...

Cancer vaccine could use immune system to fight tumors

February 27, 2014
Cincinnati Cancer Center (CCC) and UC Cancer Institute researchers have found that a vaccine, targeting tumors that produce a certain protein and receptor responsible for communication between cells and the body's immune ...

Recommended for you

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

Workouts may boost life span after breast cancer

January 22, 2018
(HealthDay)—Longer survival after breast cancer may be as simple as staying fit, new research shows.

Cancer patients who tell their life story find more peace, less depression

January 22, 2018
Fifteen years ago, University of Wisconsin–Madison researcher Meg Wise began interviewing cancer patients nearing the end of life about how they were living with their diagnosis. She was surprised to find that many asked ...

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.